ArticleKidney international reports2026
Hepcidin and Cardiovascular Events in CKD With and Without Dialysis.
Article in Kidney international reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Hepcidin's prognostic role in patients with anemia and chronic kidney disease (CKD), regardless of dialysis requirement, remains unclear. Methods: This was a Results: In ASCEND-ND and ASCEND-D, baseline hepcidin values were available for 3807 and 2881 patients (medians: 106 ng/ml and 176 ng/ml), respectively. Higher baseline hepcidin levels were associated with female sex, lower hemoglobin levels, higher transferrin saturation, higher ferritin levels, and higher C-reactive protein levels in both trials. In nondialysis patients, Kaplan-Meier (KM) curves for major adverse cardiovascular events (MACE) demonstrated that Q2 exhibited the lowest incidence, followed by Q1 and Q3, with Q4 having the highest. This association persisted after risk factor adjustment ( Conclusion: In nondialysis patients with CKD, a nonlinear relationship was observed between baseline hepcidin levels and MACE, whereas no association was found in dialysis patients. Baseline hepcidin levels did not modify the treatment effect of daprodustat compared with ESAs, irrespective of dialysis status, suggesting limited utility of hepcidin for guiding treatment selection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.